InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is reporting on its second-quarter 2024 financial results, as well as key business milestones. Highlights of the report include positive data from LGNV’s phase 2a clinical trial designed to evaluate Lomecel-B(TM) in Alzheimer’s disease being presented at the […]